Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Evgen Pharma Fundamentals

Company Name Evgen Pharma Last Updated 14 Jul 2020
Industry Health Care Sector Biotechnology
Shares in Issue (m) 136.38 Market Cap (£m) 10.98
PE Ratio -3.83 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -2.10 EPS Growth (%) 23.36
PEG -0.16 DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing -71.61 Gross Gearing 13.45
Asset Equity Ratio 1.16 Cash Equity Ratio 98.26
Quick Ratio 7.31 Current Ratio 7.31
Price To Book Value 2.61 ROCE -75.30

Evgen Pharma Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Evgen Pharma Company Financials

Assets (£m) 2020 2019 2018
Tangible Assets 0 0 0
Intangible Assets 0 0 0
Investments 0 0 0
Total Fixed Assets 0 0 0
Stocks 0 0 0
Debtors 0 0 0
Cash & Equivalents 4 2 4
Other Assets 0 0 0
Total Assets 5 3 4
Liabilities (£m) 2020 2019 2018
Creditors within 1 year 1 1 0
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 1 1 0
Net assets 4 2 4
Equity (£m) 2020 2019 2018
Called up share capital 0 0 0
Share Premium 18 13 13
Profit / Loss -3 -3 -3
Other Equity 4 4 4
Preference & Minorities 0 0 0
Total Capital Employed 4 2 4
Ratios 2020 2019 2018
Debt Ratio 0.00 0.00 0.00
Debt-to-Equity 0.00 0.00 0.00
Net Gearing -71.61 -48.66 -75.99
Gross Gearing 13.45 24.89 9.13
Assets / Equity 1.16 1.33 1.10
Cash / Equity 98.26 97.93 93.67
EPS -2.10 -2.74 -3.28
Cash Flow (£m) 2020 2019 2018
Cash from operating activities -3 -2 -2
Cashflow before financing -3 -2 -2
Increase in Cash 2 -2 -0
Income (£m) 2020 2019 2018
Turnover 0 0 0
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -3 -3 -3
Pre-Tax profit -3 -3 -3
Profit / Loss for the year 0 0 0

Evgen Pharma Company Background

Sector Biotechnology
Activities Evgen Pharma plc is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
Latest Interim Date 17 Dec 2019
Latest Fiscal Year End Date 15 Jun 2020

Evgen Pharma Directors

Appointed Director Position
2017-03-01 Richard Anthony Moulson Chief Financial Officer
2014-10-02 Dr Barry Clare Executive Chairman
2014-11-21 Dr Susan Elizabeth Foden Non-Executive Director
2018-11-08 Susan Elizabeth Clement-Davies Non-Executive Director
2015-10-14 Dr Alan John Barge Non-Executive Director

Evgen Pharma Contact Details

Company Name Evgen Pharma
Company Address Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool L3 5RF.
Company Telephone +44 (0)151 705 3532
Company Website http://www.evgen.com/

Evgen Pharma Advisors

Auditor Name Baker Tilly
Auditor Address Brazennose House, Lincoln Square, Manchester M2 5BL.
Auditor Website http://www.bakertilly.co.uk/
Auditor Telephone +44 (0)161 830 4000
Registrar Name SLC Registrars Ltd
Registrar Address 42-46 High Street, Esher KT10 9QY.
Registrar Website http://www.davidvenus.com/
Registrar Telephone +44 (0)1372 467 308
Broker Name Northland Capital Partners
Broker Address 30 Old Broad Street, London EC2N 1HT.
Broker Website http://www.northlandcp.com/
Broker Telephone +44 (0)20 7448 4400
Adviser Name Northland Capital Partners
Adviser Address 30 Old Broad Street, London EC2N 1HT.
Adviser Website http://www.northlandcp.com/
Adviser Telephone +44 (0)20 7448 4400
Solicitor Name Pinsent Masons LLP
Solicitor Address 30 Aylesbury Street, London, EC1R 0ER.
Solicitor Website http://www.pinsentmasons.com/
Solicitor Telephone +44 (0)20 7490 4000
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a